Kamada Ltd.
KMDA
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $492.7M
$8.54
▲ +3.26%
P/E
22.30
Mkt Cap
$492.7M
52-Wk Range
$6.50–$9.35
52-Week Range
$6.50 - $9.35
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 18.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary plasma-derived protein manufacturing expertise and regulatory approvals
- Strategic partnerships with global pharmaceutical leaders (Takeda, Kedrion Biopharma, PARI)
- Established portfolio of FDA-approved and internationally recognized specialty therapeutics
- High barriers to entry in biologics manufacturing and plasma collection infrastructure
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Stable outlook
Expansion of rare disease and orphan drug treatments globally
Value
Attractively priced below sector peer average
Momentum
Strong
+18.0% over 3m
Quality
Strong
Excellent business quality
Dividend
Solid
4.92% yield
Smart-money signal
Who's buying KMDA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 12, 2026
Reported EPS of $0.16 vs $0.11 consensus (+42.2% surprise). Revenue of $54.9M vs $50.8M expected (+8.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+42.2%
Revenue trend · last 8Q
—
—
+17%
+5%
+13%
+17%
+3%
+23%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$41.7M
$39.0M
$44.0M
$44.8M
$47.0M
$45.6M
$45.2M
$54.9M
Margins · last 8Q
Gross
40.9%
Operating
17.3%
Profit
16.9%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How KMDA stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.